EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia

Theodore P Ciaraldi iD, Schafer C Boeder, Sunder R Mudaliar iD, Erin R Giovannetti, Robert R Henry, Jeremy H Pettus

Diabetes, Obesity and Metabolism · 2023-07 · 25 (7) · 1985-1994

DOI: 10.1111/dom.15070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.04.2023. Verfasst von Theodore P Ciaraldi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, California, USA. Hauptthemen laut MEDLINE: Prediabetic State, Cardiovascular Diseases, Dyslipidemias. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To determine the effects of astaxanthin treatment on lipids, cardiovascular disease (CVD) markers, glucose tolerance, insulin action and inflammation in individuals with prediabetes and dyslipidaemia. Materials and Methods Adult participants with dyslipidaemia and prediabetes ( n = 34) underwent baseline blood draw, an oral glucose tolerance test and a one‐step hyperinsulinaemic‐euglycaemic clamp. They were then randomized ( n = 22 treated, 12 placebo) to receive astaxanthin 12 mg daily or placebo for 24 weeks. Baseline studies were repeated after 12 and 24 weeks of therapy.

Results

After 24 weeks, astaxanthin treatment significantly decreased low‐density lipoprotein (−0.33 ± 0.11 mM) and total cholesterol (−0.30 ± 0.14 mM) (both P < .05). Astaxanthin also reduced levels of the CVD risk markers fibrinogen (−473 ± 210 ng/mL), L‐selectin (−0.08 ± 0.03 ng/mL) and fetuin‐A (−10.3 ± 3.6 ng/mL) (all P < .05). While the effects of astaxanthin treatment did not reach statistical significance, there were trends toward improvements in the primary outcome measure, insulin‐stimulated, whole‐body glucose disposal (+0.52 ± 0.37 mg/m 2 /min, P = .078), as well as fasting [insulin] (−5.6 ± 8.4 pM, P = .097) and HOMA2‐IR (−0.31 ± 0.16, P = .060), suggesting improved insulin action. No consistent significant differences from baseline were observed for any of these outcomes in the placebo group. Astaxanthin was safe and well tolerated with no clinically significant adverse events.

Conclusions

Although the primary endpoint did not meet the prespecified significance level, these data suggest that astaxanthin is a safe over‐the‐counter supplement that improves lipid profiles and markers of CVD risk in individuals with prediabetes and dyslipidaemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prediabetic StateCardiovascular DiseasesDyslipidemiasAdultHumansAntioxidantsBlood GlucoseRisk FactorsInsulinGlucoseCholesterolHeart Disease Risk FactorsXanthophylls

Stichwörter der Autor:innen

antidiabetic drugcardiovascular diseaseclinical trialdyslipidaemiatype 2 diabetes

Substanzen

AntioxidantsBlood GlucoseInsulinGlucoseCholesterolastaxanthineXanthophylls

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, California, USA.
  • Veterans Affairs San Diego Healthcare System, San Diego, California, USA.

ORCID-Profile: Theodore P Ciaraldi, Sunder R Mudaliar

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Ciaraldi, T. P., Boeder, S. C., Mudaliar, S. R., Giovannetti, E. R., Henry, R. R., & Pettus, J. H. (2023). Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia. Diabetes, Obesity and Metabolism, 25(7), 1985-1994. https://doi.org/10.1111/dom.15070

Vancouver

Ciaraldi TP, Boeder SC, Mudaliar SR, Giovannetti ER, Henry RR, Pettus JH. Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia. Diabetes, Obesity and Metabolism. 2023;25(7):1985-1994. doi:10.1111/dom.15070

BibTeX
@article{Ciaraldi2023,
  author = {Ciaraldi, Theodore P and Boeder, Schafer C and Mudaliar, Sunder R and Giovannetti, Erin R and Henry, Robert R and Pettus, Jeremy H},
  title = {Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {7},
  pages = {1985--1994},
  doi = {10.1111/dom.15070}
}
Kostenlos starten →